Functional characterization of the novel BRAF complex mutation, BRAF V600delinsYM, identified in papillary thyroid carcinoma

International Journal of Cancer

Volumn 132, Issue 3, 2013, Pages 738-743

  Matsuse, Michiko ^a   Mitsutake, Norisato ^a   Tanimura, Susumu ^a   Ogi, Tomoo ^a   Nishihara, Eijun ^b   Hirokawa, Mitsuyoshi ^b   Fuziwara, Cesar S ^a   Saenko, Vladimir A ^a   Suzuki, Keiji ^a   Miyauchi, Akira ^b   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b KUMA HOSPITAL   (Japan)

Author keywords

BRAF; mutation; papillary thyroid carcinoma; V600delinsYM

Indexed keywords

ADENINE; B RAF KINASE; CYTOSINE; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOTIDE; PHOSPHOTRANSFERASE; SORAFENIB; THYMINE; VALINE;

ANIMAL CELL; ARTICLE; BRAFV600DELINSYM GENE; CANCER PATIENT; CELL STRAIN 3T3; CELL TRANSFORMATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; EXON; GENE; GENE INSERTION; GENE MUTATION; IN VITRO STUDY; JAPANESE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PREDICTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA; WESTERN BLOTTING;

3T3 CELLS; AMINO ACID SUBSTITUTION; ANIMALS; BENZENESULFONATES; CARCINOMA; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; COS CELLS; DNA, NEOPLASM; HUMANS; MICE; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; THYROID NEOPLASMS;

EID: 84870252590     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27709     Document Type: Article

References (24)

1. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
2. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22: 4578-80.
3. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004; 23: 7436-40.
4. Xing M,. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-62.
5. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004; 202: 247-51.
6. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumor aggressiveness. Virch Arch 2005; 446: 589-95.
7. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 213-20.
8. De Falco V, Giannini R, Tamburrino A, et al. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab 2008; 93: 4398-402.
9. Trovisco V, Soares P, Soares R, et al. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 2005; 36: 694-7.
10. Oler G, Ebina KN, Michaluart P, Jr, et al. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 2005; 62: 509-11.
11. Hou P, Liu D, Xing M,. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007; 6: 377-9.
12. Carta C, Moretti S, Passeri L, et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) 2006; 64: 105-9.
13. Moretti S, Macchiarulo A, De Falco V, et al. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006; 25: 4235-40.
14. Santarpia L, Sherman SI, Marabotti A, et al. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol 2009; 40: 827-33.
15. Chiosea S, Nikiforova M, Zuo H, et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009; 20: 122-6.
16. Barzon L, Masi G, Boschin IM, et al. Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Eur J Endocrinol 2008; 159: 77-80.
17. Trovisco V, Couto JP, Cameselle-Teijeiro J, et al. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008; 69: 683-5.
18. den Dunnen JT, Antonarakis SE,. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7-12.
19. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67.
20. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
21. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Nature 2010; 464: 427-30.
22. Kelley LA, Sternberg MJ,. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 2009; 4: 363-71.
23. Matsuse M, Takahashi M, Mitsutake N, et al. The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J Med Genet 2011; 48: 645-8.
24. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.